Teva Pharmaceutical Industries (TEVA) Earns Sell Rating from Wells Fargo & Co

Wells Fargo & Co restated their sell rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Tuesday morning.

Several other equities analysts have also issued reports on TEVA. Leerink Swann cut their price target on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an underperform rating on the stock in a research note on Friday, February 9th. Gabelli lowered Teva Pharmaceutical Industries from a buy rating to a hold rating and set a $19.00 price target on the stock. in a research note on Friday, February 9th. Oppenheimer reaffirmed a hold rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Bank of America cut their price target on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an underperform rating on the stock in a research note on Friday, February 9th. Finally, Maxim Group reaffirmed a hold rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Ten research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $21.26.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) opened at $20.90 on Tuesday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.66 and a current ratio of 0.86. The company has a market capitalization of $21,142.96, a price-to-earnings ratio of -1.29, a PEG ratio of 1.80 and a beta of 0.60. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.77 by $0.14. The company had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.38 earnings per share. research analysts expect that Teva Pharmaceutical Industries will post 2.31 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after acquiring an additional 6,009,897 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $118,487,000. Schroder Investment Management Group increased its holdings in shares of Teva Pharmaceutical Industries by 22.7% in the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after acquiring an additional 1,147,683 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 4.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock worth $106,271,000 after acquiring an additional 259,891 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Teva Pharmaceutical Industries by 5.1% in the second quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after acquiring an additional 232,924 shares in the last quarter. Institutional investors own 51.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries (TEVA) Earns Sell Rating from Wells Fargo & Co” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2018/02/17/teva-pharmaceutical-industries-teva-earns-sell-rating-from-wells-fargo-co-2.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply